You are here

Study of PKI-179 Administered Orally to Subjects With Solid Tumors

Last updated on December 15, 2017

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Advanced Malignant Solid Tumors
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Male or female subjects age 18 years or older.

2. Part 1/MTD Estimation Phase: Pathologic diagnosis of any solid tumor. Part 2/MTD
Confirmation Phase: Pathologic diagnosis of one of the following tumor types: breast,
non-small cell lung, ovarian, endometrial, or colorectal cancer or glioblastoma.

3. Availability of either formalin-fixed paraffin-embedded (FFPE) tumor tissue block or
unstained slides for exploratory biomarker analysis.

4. Incurable cancer, with disease progression following at least 1 conventional,
standard, or investigational therapy with no further standard treatment available in
the opinion of the investigator.

5. At least 1 evaluable lesion as defined by Response Evaluation Criteria in Solid Tumors
(RECIST) criteria.

6. Eastern Cooperative Oncology Group (ECOG) 0 to 2.

7. Acceptable laboratory values, including fasting serum glucose.

8. All male and female subjects who are biologically capable of having children, must
agree to use a medically acceptable method of birth control for the duration of the
study (e.g., condom with a spermicide) and for 12 weeks after the last dose of
investigational product. All female subjects who are biologically capable of having
children must have a negative serum pregnancy test result before first dose of
investigational product. Any pregnancy that occurs in the female partner of a male
subject in the trial must be reported if it occurs at any time during the active
treatment phase of the study or for 12 weeks after the last dose of investigational
product.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Major surgery, chemotherapy, radiotherapy, investigational therapy, or other cancer
therapy within 2 weeks prior to first dose of investigational product.

2. Lack of recovery from any prior surgery, chemotherapy, radiotherapy, or other cancer
therapy.

3. Clinically unstable primary or metastatic central nervous system (CNS) tumors.
Subjects with progression of CNS tumors are eligible as long as they have been
clinically stable for at least 4 weeks before first dose of PKI-179 (no significant
change in anticonvulsant doses, mental status, or clinical symptoms related to the CNS
tumors).

4. Subjects with known diabetes.

5. QTc interval > 470 ms.

6. Pregnant or breastfeeding women.

7. Evidence of significant medical illness or abnormal laboratory finding that in the
opinion of the investigator would substantially increase the risk associated with the
subject's participation in the study or impact the assessment of safety and/or
efficacy. Examples include, but are not limited to: uncontrolled seizures, serious
ongoing active infection requiring treatment, significant uncontrolled cardiac
disease, such as congestive heart failure, myocardial infarction within past 6 months,
angina requiring treatment, or other clinically significant or uncontrolled
conditions.

NCT00997360
Pfizer
Terminated
Study of PKI-179 Administered Orally to Subjects With Solid Tumors

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Part 1, MELANOMA, SCCHN, OVCA, SARCOMA, OTHER SOLID TUMORS, Part 1 and 2, NSCLC, UROTHELIAL CARCINOMA
NCT02573259
All Genders
18+
Years
Multiple Sites
Advanced Breast Cancer, Metastatic Breast Cancer
NCT03280303
All Genders
18+
Years
Multiple Sites
Androgen Receptor Positive Triple Negative Breast Cancer Advanced
NCT01889238
Females
18+
Years
Multiple Sites
Study of PKI-179 Administered Orally to Subjects With Solid Tumors
A Phase 1 Study of PKI-179 Administered Orally to Subjects With Solid Tumors
This is an open label dose escalation study to find the maximum tolerated dose (MTD) of PKI-179 in subjects with solid tumors. Part 1 of the study will be the dose estimation phase and will be open to subjects with all solid tumors. Part 2 will be the dose confirmation phase and will be open to subjects with breast, non small cell lung, ovarian, endometrial, or colorectal cancer or glioblastoma. All subjects will receive daily oral dosing of PKI-179. A continuous reassessment method (CRM) design will be used, which will take into account dose limiting toxicity (DLT) information from each dose level explored in order to determine the next dose level.
Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Advanced Malignant Solid Tumors
Drug: PKI-179
Experimental: 1
PKI-179
Intervention: Drug: PKI-179
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
80
February 2012
February 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male or female subjects age 18 years or older.
  2. Part 1/MTD Estimation Phase: Pathologic diagnosis of any solid tumor. Part 2/MTD Confirmation Phase: Pathologic diagnosis of one of the following tumor types: breast, non-small cell lung, ovarian, endometrial, or colorectal cancer or glioblastoma.
  3. Availability of either formalin-fixed paraffin-embedded (FFPE) tumor tissue block or unstained slides for exploratory biomarker analysis.
  4. Incurable cancer, with disease progression following at least 1 conventional, standard, or investigational therapy with no further standard treatment available in the opinion of the investigator.
  5. At least 1 evaluable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
  6. Eastern Cooperative Oncology Group (ECOG) 0 to 2.
  7. Acceptable laboratory values, including fasting serum glucose.
  8. All male and female subjects who are biologically capable of having children, must agree to use a medically acceptable method of birth control for the duration of the study (e.g., condom with a spermicide) and for 12 weeks after the last dose of investigational product. All female subjects who are biologically capable of having children must have a negative serum pregnancy test result before first dose of investigational product. Any pregnancy that occurs in the female partner of a male subject in the trial must be reported if it occurs at any time during the active treatment phase of the study or for 12 weeks after the last dose of investigational product.

Exclusion criteria:

  1. Major surgery, chemotherapy, radiotherapy, investigational therapy, or other cancer therapy within 2 weeks prior to first dose of investigational product.
  2. Lack of recovery from any prior surgery, chemotherapy, radiotherapy, or other cancer therapy.
  3. Clinically unstable primary or metastatic central nervous system (CNS) tumors. Subjects with progression of CNS tumors are eligible as long as they have been clinically stable for at least 4 weeks before first dose of PKI-179 (no significant change in anticonvulsant doses, mental status, or clinical symptoms related to the CNS tumors).
  4. Subjects with known diabetes.
  5. QTc interval > 470 ms.
  6. Pregnant or breastfeeding women.
  7. Evidence of significant medical illness or abnormal laboratory finding that in the opinion of the investigator would substantially increase the risk associated with the subject's participation in the study or impact the assessment of safety and/or efficacy. Examples include, but are not limited to: uncontrolled seizures, serious ongoing active infection requiring treatment, significant uncontrolled cardiac disease, such as congestive heart failure, myocardial infarction within past 6 months, angina requiring treatment, or other clinically significant or uncontrolled conditions.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00997360
3266A1-1002
No
Not Provided
Not Provided
Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
December 2009

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now